Biopharma manufacturing company Repligen Corporation (NASDAQ: RGEN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 10.9% year on year to $209.3 million. The company’s full-year revenue guidance of $848 million at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.53 per share was 14.5% above analysts’ consensus estimates.
Is now the time to buy RGEN? Find out in our full research report (it’s free for active Edge members).
Repligen (RGEN) Q3 2026 highlights:
- Revenue $209.3 million vs S&P analysts’ estimates of $207 million (10.9% year-on-year growth, 1.1% beat)
- Adjusted EPS $0.53 vs S&P analysts’ estimates of $0.46 (14.5% beat)
- Adjusted EBITDA $43.84 million vs analyst estimates of $38.81 million (20.9% margin, 13% beat)
- Revenue guidance The company lifted its revenue guidance for the full year to $848 million at the midpoint from $824 million, a 2.9% increase
- Adjusted EPS guidance Management slightly raised its full-year adjusted EPS guidance to $2.07 at the midpoint
- Operating margin -14.1%, down from 8.9% in the same quarter last year
- Organic revenue rose 12.5% year on year (beat)
- Market capitalization $10.69 billion
StockStory’s take
Repligen’s third quarter was marked by revenue and non-GAAP profit that exceeded Wall Street expectations, driving a positive market reaction. Management attributed this performance to robust organic growth in proteins and chromatography segments, as well as continued strength in analytics and services. CEO Olivier Loeillot highlighted that the bioprocessing industry is recovering, with capital equipment order activity reaching a five-year high, despite muted revenue in that area. The addition of BioLife also contributed to Repligen’s diversified growth.
Looking forward, Repligen’s improved full-year guidance is underpinned by the anticipated contribution from the BioLife acquisition, growing demand in cell therapy, and a strong backlog in capital equipment. Management emphasized prudent integration planning and early realization of operating expense synergies, while also acknowledging ongoing investments in automation and AI to support future growth. CFO Jason Garland noted that the company is balancing margin expansion with necessary spending, stating, “We will remain thoughtful about balancing investments in the business and expanding margins.”
Key insights from management’s remarks
Management credited strong momentum in proteins, chromatography, and analytics, alongside BioLife’s integration, for driving above-market growth in Q3. They also noted that capital equipment order trends point to improving industry demand.
- Proteins and chromatography surge: Both segments saw significant growth in Q3, with proteins up over 40% and chromatography revenue growing more than 50%. Management noted these rates were aided by favorable prior year comparisons, and clarified that full-year guidance is for 'mid-teens growth' in proteins and 'at least 30%' in chromatography. This puts the Q3 surge in the context of expected moderation over the full year.
- BioLife acquisition integration: The recent closing of the BioLife deal expands Repligen’s reach in cell therapy. Management reported early progress on operating expense synergies and cross-training of commercial teams, with expectations for revenue synergies and expanded customer access, especially in Asia.
- Analytics franchise momentum: The analytics segment marked a record quarter, highlighted by the adoption of Repligen’s SoloVPE PLUS technology into industry-wide quality standards. Management expects this external validation to drive wider customer adoption and product pull-through.
- Capital equipment backlog building: Orders for capital equipment rose mid-teens year-over-year, reaching the highest level in five years. However, management emphasized that this refers to orders, not revenue, and that the revenue from these orders is expected primarily in 2027, indicating a lag between order intake and realized sales.
- Filtration segment headwinds: Filtration revenue declined due to customer-specific headwinds and product divestitures. Management remains confident in a return to growth for this segment in 2027, citing a strong backlog and new customer wins, particularly in biosimilars.
Drivers of future performance
Management expects Repligen’s future performance to be driven by BioLife’s contribution, cell therapy growth, and a rebound in capital equipment, while monitoring inflation and competitive dynamics.
- BioLife contribution and integration: The acquisition of BioLife is expected to drive both revenue and margin expansion, with management projecting at least $0.05 accretion to non-GAAP EPS in 2027. Early synergies are being realized, and commercial teams are working to unlock further cross-selling opportunities, particularly in Asia and cell therapy markets.
- Capital equipment and on-shoring demand: A strong order backlog for capital equipment positions Repligen for a rebound in this segment next year. Management believes that broader industry trends, such as increased on-shoring and large-scale manufacturing expansion, could accelerate equipment sales as customers finalize capital allocation decisions.
- Margin management and automation: Investments in automation, AI, and operational efficiency are central to Repligen’s strategy for offsetting inflationary pressures and supporting margin expansion. Management aims to balance these investments with disciplined cost control to achieve long-term EBITDA margin targets.
Catalysts in upcoming quarters
In the coming quarters, our analysts will focus on (1) the pace of BioLife integration and realization of promised synergies, (2) whether capital equipment order momentum translates into revenue growth as industry investment picks up, and (3) the sustainability of strong analytics and protein segment performance. Developments in cell and gene therapy approvals and the progression of on-shoring initiatives will also be critical markers of execution.
Repligen currently trades at $173.44, down from $180.17 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Stocks that trumped tariffs
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
